Healthcare & Biotech

SHERIDAN, WYOMING – May 9, 2025 – LivaNova PLC, a leading global medical technology company, has announced 12-month top-line data from its OSPREY clinical trial. The study demonstrates promising results for the aura6000™ System, an investigational device designed to treat moderate to severe obstructive sleep apnea (OSA). The data highlights sustained improvements in key health metrics, positioning the aura6000™ as a potential breakthrough in OSA management.

Strong Results from 12-month OSPREY Data

The OSPREY trial's 12-month data shows significant improvements for patients receiving the aura6000™ System, demonstrating the effectiveness of proximal hypoglossal nerve stimulation (p-HGNS) in managing OSA. The results confirm the system’s potential as a long-term solution for patients with moderate to severe cases who have previously struggled with conventional treatments.

Key highlights from the study include:

SHERIDAN, WYOMING – May 09, 2025 – Globus Medical, Inc. (NYSE: GMED), a leading provider of musculoskeletal solutions, has announced its financial results for the first quarter of 2025. The company reported worldwide net sales of $598.1 million, reflecting a 1.4% decrease year-over-year, primarily driven by a slowdown in Enabling Technology deal closures and temporary supply chain disruptions. Despite these challenges, Globus Medical saw notable growth in its core U.S. spine business and remains optimistic about its future prospects.

SHERIDAN, WYOMING – May 9, 2025 – Globus Medical, Inc. (NYSE: GMED), a prominent player in the musculoskeletal solutions industry, has reported its financial results for the first quarter of 2025. Despite a slight dip in global net sales, the company remains confident in its ability to drive long-term growth and innovation. The results reflect challenges faced in certain areas, including slower deal closures in Enabling Technology, but also showcase the company’s strong positioning in the U.S. spine business.

SHERIDAN, WYOMING – May 9, 2025 – Enovis Corporation (NYSE: ENOV), a global leader in medical technology, has appointed Damien McDonald as its new Chief Executive Officer, effective May 12, 2025. McDonald, who will also join the Enovis Board of Directors following the Company’s 2025 Annual Meeting of Stockholders, succeeds Matt Trerotola, who has announced his retirement. This strategic leadership transition positions Enovis for continued growth and innovation in the medical technology sector.

SHERIDAN, WYOMING – May 8, 2025 – Invacare is proud to announce the launch of its global fundraiser, Move For Mobility 2025, which aims to provide life-changing wheelchairs to individuals in need around the world. The initiative brings together Invacare employees, ambassadors, clients, and partners in a worldwide effort to raise awareness and funds for the Free Wheelchair Mission, an organization committed to delivering wheelchairs at no cost to people with disabilities in remote communities.

A Strong Partnership with Free Wheelchair Mission

Since its inception, Invacare has partnered with Free Wheelchair Mission, a humanitarian non-profit organization, to help deliver mobility solutions to underserved populations globally. This year marks the sixth year of this partnership, with Invacare contributing its engineering, testing, and distribution expertise to help create durable and effective wheelchairs.

SHERIDAN, WYOMING – May 8, 2025 – Mölnlycke Health Care has reiterated its unwavering support for the Wound Care Collaborative Community (WCCC) initiative, which seeks to develop a standardized pre-clinical testing framework for wound dressings. The collaboration aims to drive improvements in patient care by ensuring more consistent and clinically relevant product evaluations across the wound care industry.

The initiative brings together clinicians, materials management teams, regulators, and industry experts with a shared vision: to refine wound dressing standards that better reflect real-world needs. Mölnlycke Health Care has been a steadfast partner in this project, working with leading players in the wound care sector to enhance product development and improve patient outcomes.

SHERIDAN, WYOMING – May 8, 2025 – Fresenius Medical Care has kicked off fiscal year 2025 with robust financial performance, driven by strong organic revenue growth and significant operational efficiencies. The world’s leading provider of dialysis products and services posted a 5% increase in organic revenue, highlighting continued operational improvements in both its Care Enablement and Care Delivery segments.

Strong Financial Results in Q1 2025

In the first quarter of 2025, Fresenius Medical Care achieved notable revenue growth, with total sales rising 3% year-on-year, and organic growth accounting for a 5% increase. The company’s total revenue for Q1 amounted to EUR 4,881 million. Despite the challenges posed by a severe flu season, which impacted dialysis treatment volumes in the U.S., the company demonstrated resilience through its diversified service offerings and strategic operational improvements.

SHERIDAN, WYOMING – May 8, 2025 – Fresenius Medical Care (FME) celebrates a major milestone as its dialysis center in Sokolov, Czech Republic, marks its 40th anniversary. With a commitment to providing high-quality care, NephroCare, under the FME brand, continues to serve around 100 dialysis patients, offering specialized nephrological services and cutting-edge dialysis treatments.

Pioneering Dialysis Care in the Czech Republic

The Sokolov dialysis center, located in the western Bohemia region, was founded in 1985 and has been at the forefront of chronic kidney disease treatment in the Czech Republic. From the beginning, the center’s innovative approach and dedication to patient well-being have set it apart.

SHERIDAN, WYOMING – May 8, 2025 – B. Braun Group has demonstrated resilience and strategic growth amidst challenging global conditions, reporting a 4.4% increase in sales for the 2024 fiscal year. The company’s focus on innovation, operational efficiency, and modern technology investments has contributed to a solid financial performance, reaffirming its commitment to advancing healthcare solutions worldwide.

Robust Financial Growth and Increased Efficiency

In a year marked by rising costs and market volatility, B. Braun’s fiscal year 2024 results showcase the company’s ability to drive growth and improve profitability. The company’s sales surged to 9.1 billion euros, up from 8.8 billion euros the previous year. At constant exchange rates, this represents a notable 6.8% increase, aligning with B. Braun’s long-term growth target of 5-7%.

Key highlights from the 2024 fiscal year include:

SHERIDAN, WYOMING – May 8, 2025 – Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care, today revealed the successful outcome of all proposed resolutions at its 2025 Annual General Meeting (AGM). Among the significant decisions, shareholders approved key appointments to the Board, including the election of Deborah Di Sanzo, and granted approval for the 2024 Compensation Report and the Report on Non-Financial Matters.

Key Appointments and Re-elections

At the 2025 AGM, shareholders re-elected F. Michael Ball as Chair of the Board of Directors, alongside several other members who stood for re-election. This includes Lynn Bleil, Arthur Cummings, David Endicott, Thomas Glanzmann, D. Keith Grossman, Scott Maw, Karen May, Ines Pöschel, and Dieter Spälti. These appointments ensure the continued leadership and strategic direction of Alcon for the upcoming term.